Articles related to SCHIZOPHRENIA

SEP-363856, a non-D2-receptor binding antipsychotic, reduced the PANSS total score from baseline more than the placebo in this 4-week experiment comprising individuals with acute exacerbations of schizophrenia. Longer and larger trials are required to confirm SEP-363856’s effects and side effects as well as its efficacy in comparison to other medications currently used to treat schizophrenia patients.

According to psychiatrist Russell Margolis, clinical director of the new Johns Hopkins Precision Medicine Center of Excellence for Schizoaffective Disorders, the goal of the center is to create individualized treatment plans for patients, based on the idea that the disorders can be divided into three subtypes: Those who will likely respond favorably to traditional antipsychotics Those who do respond to clozapine but do not respond to traditional antipsychotics Individuals who do not respond to any drugs at all (ultra treatment resistance)

In a study of more than 22,000 patients with schizophrenia, schizoaffective disorder, or bipolar disorder, 24% also had obsessive-compulsive symptoms; 12% had a diagnosis of OCD. Both co-morbidities were associated with higher rates of aggressive behavior, cognitive problems, and hallucinations or delusions.

A quartet of current clinical trials involving first-in-class molecules and CRISPR gene editing show great promise. STELLAR investigates a fusion protein in PAH, CodeBreak 200 studies a first-in-class of KRAS inhibitor, EMERGENT-2 focuses on a new treatment for schizophrenia, and NCT04601051 studies a gene editing drug for one form of amyloidosis.

News, comments, and analysis from the field of psychiatry, including the FDA’s clearance of a new neuromodulation device for people with significant depression, a phase III safety and efficacy trial of an injectable subcutaneous formulation of olanzapine for schizophrenia, melatonin dependence, and much more.

Kar-XT adds trospium to xanomeline to substantially improve the second agent’s tolerability, enabling its use to reduce both positive and negative symptoms in schizophrenia. Allopregnanolone, an oral version of brexanolone, is being investigated in MDD. The dextromethorphan and bupropion combo, AXS-05, seeks to offer a new antidepressant option and hydroxynorketamine promises MDD treatment without ketamine’s dissociative effects and abuse potential.